The headlines about the US government’s decisions on price interventions for Pfizer Inc./Astellas Pharma, Inc.’s Xtandi brings to mind the old phrase about getting out of the frying pan and into the fire.
The headlines are about a decision not to take on Xtandi’s price, when the Department of Health & Human Services announced that it is denying a petition calling for the National Institutes of Health to invoke “march in” rights on patents associated with the cancer therapy enzalutamide
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?